In summary, we found that the upregulated lncRNA CDKN2B-AS1 acts as an essential oncogene, promotes tumor malignant progression in vitro and in vivo, and correlates with poor prognosis in KIRC. This evidence concerns the gene CDKN2B and neoplasm.